Literature DB >> 18823068

Active drug safety surveillance: a tool to improve public health.

Richard Platt1, Leanne Madre, Robert Reynolds, Hugh Tilson.   

Abstract

PURPOSE: Ensuring that drugs have an acceptable safety profile and are used safely is a major public health priority. The Centers for Education and Research on Therapeutics (CERTs) convened experts from academia, government, and industry to assess strategies to increase the speed and predictive value of generating and evaluating safety signals, and to identify next steps to improve the US system for identifying and evaluating potential safety signals.
METHODS: The CERTs convened a think tank comprising representatives of the groups noted above to address these goals.
RESULTS: Participants observed that, with the increasing availability of electronic health data, opportunities have emerged to more accurately characterize and confirm potential safety issues. The gain for public health from a highly coordinated network of population-based databases for active surveillance is great and within reach, although operational questions remain. A collaborative network must create a working definition of a safety signal, screening algorithms, and criteria and strategies to confirm or refute a signal once identified through screening. Guidelines are needed for when and how to communicate a signal exists and is being evaluated, as well as the outcome of that evaluation.
CONCLUSION: A public-private partnership to create a network of government and private databases to routinely evaluate and prioritize safety questions is in the public interest. Better methods are needed, and a knowledgeable workforce is required to conduct the surveillance and understand how to interpret the results. The international community will benefit from the availability of better methods and more experts. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18823068     DOI: 10.1002/pds.1668

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  11 in total

1.  Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

Authors:  Peter M Wahl; Joshua J Gagne; Thomas E Wasser; Debra F Eisenberg; J Keith Rodgers; Gregory W Daniel; Marcus Wilson; Sebastian Schneeweiss; Jeremy A Rassen; Amanda R Patrick; Jerry Avorn; Rhonda L Bohn
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis.

Authors:  Ben Y Reis; Karen L Olson; Lu Tian; Rhonda L Bohn; John S Brownstein; Peter J Park; Mark J Cziraky; Marcus D Wilson; Kenneth D Mandl
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

3.  Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases.

Authors:  Henrik Svanström; Torbjörn Callréus; Anders Hviid
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

4.  Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure.

Authors:  Suraj J Patel; Jack M Milwid; Kevin R King; Stefan Bohr; Arvin Iracheta-Vellve; Arvin Iracheta-Velle; Matthew Li; Antonia Vitalo; Biju Parekkadan; Rohit Jindal; Martin L Yarmush
Journal:  Nat Biotechnol       Date:  2012-01-15       Impact factor: 54.908

Review 5.  Predicting the clinical relevance of drug interactions from pre-approval studies.

Authors:  Silvio Caccia; Silvio Garattini; Luca Pasina; Alessandro Nobili
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data.

Authors:  V Hoffman; F Xue; B Gardstein; K Skerry; C W Critchlow; C Enger
Journal:  Osteoporos Int       Date:  2015-11-11       Impact factor: 4.507

7.  Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury.

Authors:  Young-Eun Cho; Eun-Ju Im; Pyong-Gon Moon; Esteban Mezey; Byoung-Joon Song; Moon-Chang Baek
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

8.  A compilation of research working groups on drug utilisation across Europe.

Authors:  Mònica Sabaté; Juan Fernando Pacheco; Elena Ballarín; Pili Ferrer; Hans Petri; Joerg Hasford; Marieke Wilma Schoonen; Marietta Rottenkolber; Joan Fortuny; Joan-Ramon Laporte; Luisa Ibáñez
Journal:  BMC Res Notes       Date:  2014-03-13

9.  Pharmacovigilance Considerations for Biosimilars in the USA.

Authors:  Gustavo Grampp; Thomas Felix
Journal:  BioDrugs       Date:  2015-10       Impact factor: 5.807

Review 10.  Circulating liver-specific microRNAs in cynomolgus monkeys.

Authors:  Takuma Iguchi; Ken Sakurai; Satoshi Tamai; Kazuhiko Mori
Journal:  J Toxicol Pathol       Date:  2017-09-08       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.